DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
← catalyst calendarNCT06388421 · readout in 1,474 d
Sponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
900estimated
Sites
67
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-23 | actual | When the study began enrolling |
| Primary completion | 2030-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Pulmonary Hypertension
- Interstitial Lung Disease
Intervention
- Other: Prospective study assessments
Primary outcome
what the primary-completion date above is the date OFBaseline characteristics as described by demographics, medical history, ILD history, PH history, family history (comorbidities), and diagnostic right heart catheterization values.
measured Baseline
Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed